Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience's stock (ANRO) has experienced significant volatility in the past six months, with a 52-week range between $1.60 and $20.91. As of early February 2026, the stock price has been around $14-$16. The stock saw a high of $20.91 on December 19, 2025. Over the past year, ANRO has delivered a 259.87% change. The company went public with its IPO on February 1, 2024, at $16.00 per share.

As a clinical-stage biopharmaceutical company, Alto Neuroscience, Inc. is focused on research and development, and its products are not yet commercially available. Therefore, there is no discernible demand seasonality for its products and services at this stage.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company in Mountain View, California, focused on developing precision medicines for neuropsychiatric disorders. The company uses its Alto Intelligence™ platform, which integrates machine learning algorithms with EEG data, to identify patient subgroups and predict treatment response. ALTO-100 is in Phase 2b clinical trial for bipolar depression. ALTO-300, a melatonergic agonist and serotonergic antagonist, is in Phase 2b clinical trial for major depressive disorder. ALTO-101, a phosphodiesterase 4 inhibitor, is in Phase 2 proof-of-concept trial for cognitive impairment associated with schizophrenia. ALTO-203, a histamine H3 receptor inverse agonist, is in Phase 2 POC trial for MDD patients with higher levels of anhedonia. ALTO-202, an antagonist of the GluN2B subunit of the NMDA receptor, is in Phase 1 clinical trial for MDD. ALTO-207 and ALTO-208 are also listed as product candidates.

Alto Neuroscience, Inc. is headquartered in Mountain View, California, and operates primarily in the United States as a clinical-stage biopharmaceutical entity.

Alto Neuroscience has maintained a positive brand reputation over the past year, marked by scientific and clinical advancements. The company reported positive Phase 1 results for ALTO-101, favorable outcomes from an interim analysis of its ALTO-300 Phase 2b MDD trial, and completed enrollment in the ALTO-203 Phase 2 proof-of-concept MDD trial. Alto Neuroscience has strengthened its intellectual property portfolio with recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker-defined populations. Analyst ratings reflect a "Moderate Buy" consensus, and the company's stock performance has exceeded the US Pharmaceuticals industry and the broader US Market.

Alto Neuroscience, Inc. has 111 institutional owners and shareholders, holding a total of 17,295,036 shares. Major institutional shareholders include Falcon Edge Capital, LP, Armistice Capital, Llc, Vanguard Group Inc, Point72 Asset Management, L.P., Franklin Resources Inc, Vestal Point Capital, LP, Marshall Wace, Llp, Commodore Capital LP, Perceptive Advisors LLC, K2 Healthventures Equity Trust LLC and Alkeon Capital Management Llc. Individual ownership includes Amit Etkin, the Founder, Chairman of the Board, CEO & President, who made buy transactions in February 2024, along with other insiders such as Chief Medical Officer Adam Savitz and CFO & Chief Business Officer Nicholas Smith.